SCHEMBL21361462

SCHEMBL21361462

CN(C)c1ccc(S(=O)(=O)N2CCCN(CC3CCCCC3)CCCN(S(=O)(=O)N3CCC(c4ccccc4)CC3)CCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.46
HTT P42858 2/20 0.46
USP5 P45974 3/20 0.45
TSHR P16473 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
CCR5 P51681 1/20 0.45
STAT3 P40763 1/20 0.45
RAB9A P51151 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 1/20 0.43
APOBEC3A P31941 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.40
CCR2 P41597 1/20 0.40
USP2 O75604 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361592 0.99 LMNA (0.48) LMNAHTTUSP5TSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL21359148 0.98 LMNA (0.47) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL21361543 0.94 CCR5 (0.41) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL23102100 0.94 CCR5 (0.41) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL21361530 0.93 NPSR1 (0.46) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL21358919 0.93 LMNA (0.41) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL21359059 0.93 LMNA (0.44) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL21361625 0.93 NPSR1 (0.46) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL21358939 0.93 NPSR1 (0.46) LMNAHTTUSP5TSHRSMN1; SMN2
SCHEMBL21361509 0.92 CD4 (0.46) LMNAHTTUSP5TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G LMNA 4550/4885HTT 2931/4885USP5 1549/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G LMNA 4448/4885HTT 3046/4885USP5 1757/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G LMNA 4555/4885HTT 3038/4885USP5 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.